Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025
Compugen (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company specializing in AI/ML-powered drug target discovery, has scheduled its second quarter 2025 financial results release for Wednesday, August 6, 2025, before U.S. markets open.
The company will host a conference call and webcast at 8:30 AM ET to discuss the results and provide a corporate update. Investors can access the call via phone (U.S.: 1-866-744-5399, International: +972-3-918-0644) or through Compugen's website. A replay will be available on the website after the live event.
Compugen (NASDAQ: CGEN), un'azienda in fase clinica specializzata nell'immunoterapia oncologica e nella scoperta di target farmacologici supportata da AI/ML, ha programmato la pubblicazione dei risultati finanziari del secondo trimestre 2025 per mercoled矛 6 agosto 2025, prima dell'apertura dei mercati statunitensi.
L'azienda terr脿 una conference call e una webcast alle 8:30 AM ET per discutere i risultati e fornire un aggiornamento aziendale. Gli investitori potranno partecipare alla chiamata tramite telefono (USA: 1-866-744-5399, Internazionale: +972-3-918-0644) o attraverso il sito web di Compugen. Una registrazione sar脿 disponibile sul sito dopo l'evento live.
Compugen (NASDAQ: CGEN), una empresa en etapa cl铆nica especializada en inmunoterapia contra el c谩ncer y en el descubrimiento de objetivos farmacol贸gicos impulsado por IA/ML, ha programado la publicaci贸n de sus resultados financieros del segundo trimestre de 2025 para el mi茅rcoles 6 de agosto de 2025, antes de la apertura de los mercados en EE.UU.
La compa帽铆a realizar谩 una llamada conferencia y una transmisi贸n web a las 8:30 AM ET para discutir los resultados y brindar una actualizaci贸n corporativa. Los inversores podr谩n acceder a la llamada por tel茅fono (EE.UU.: 1-866-744-5399, Internacional: +972-3-918-0644) o a trav茅s del sitio web de Compugen. Una repetici贸n estar谩 disponible en el sitio despu茅s del evento en vivo.
Compugen (NASDAQ: CGEN)電� AI/ML 旮半皹 鞎诫 韮�瓴� 氚滉荡鞚� 鞝勲鞙茧 頃橂姅 鞛勳儊 雼硠 鞎� 氅挫棴旃橂 須岇偓搿�, 2025雲� 2攵勱赴 鞛 瓴瓣臣毳� 2025雲� 8鞗� 6鞚� 靾橃殧鞚� 氙戈淡 鞁滌灔 臧滌灔 鞝� 氚滍憸頃� 鞓堨爼鞛呺媹雼�.
须岇偓电� 霃欕秬 響滌鞁� 旮办 鞓れ爠 8鞁� 30攵�鞐� 瓴瓣臣毳� 雲检潣頃橁碃 旮办梾 鞐呺嵃鞚错姼毳� 鞝滉车頃橁赴 鞙勴暣 旎嵓霟办姢 旖滉臣 鞗轨簮鞀ろ姼毳� 歆勴枆頃╇媹雼�. 韴瀽鞛愲摛鞚� 鞝勴檾(氙戈淡: 1-866-744-5399, 甑牅: +972-3-918-0644) 霕愲姅 Compugen 鞗轨偓鞚错姼毳� 韱淀暣 彀胳棳頃� 靾� 鞛堨姷雼堧嫟. 靸濎瓿� 頉� 鞗轨偓鞚错姼鞐愳劀 雼れ嫓氤搓赴毳� 鞚挫毄頃� 靾� 鞛堨姷雼堧嫟.
Compugen (NASDAQ : CGEN), une soci茅t茅 en phase clinique sp茅cialis茅e dans l'immunoth茅rapie du cancer et la d茅couverte de cibles m茅dicamenteuses assist茅e par IA/ML, a pr茅vu la publication de ses r茅sultats financiers du deuxi猫me trimestre 2025 pour le mercredi 6 ao没t 2025, avant l'ouverture des march茅s am茅ricains.
La soci茅t茅 organisera une conf茅rence t茅l茅phonique et une webdiffusion 脿 8h30 ET pour discuter des r茅sultats et fournir une mise 脿 jour d'entreprise. Les investisseurs pourront acc茅der 脿 l'appel par t茅l茅phone (脡tats-Unis : 1-866-744-5399, International : +972-3-918-0644) ou via le site web de Compugen. Une rediffusion sera disponible sur le site apr猫s l'茅v茅nement en direct.
Compugen (NASDAQ: CGEN), ein klinisch fortgeschrittenes Krebsimmuntherapie-Unternehmen, das sich auf die Entdeckung von Arzneimittelzielen mit KI/ML spezialisiert hat, hat die Ver枚ffentlichung der Finanzergebnisse 蹿眉谤 das zweite Quartal 2025 蹿眉谤 Mittwoch, den 6. August 2025, vor der 脰ffnung der US-M盲rkte geplant.
Das Unternehmen wird um 8:30 Uhr ET eine Telefonkonferenz und Webcast abhalten, um die Ergebnisse zu besprechen und ein Unternehmensupdate zu geben. Investoren k枚nnen 眉ber Telefon (USA: 1-866-744-5399, International: +972-3-918-0644) oder 眉ber die Website von Compugen teilnehmen. Eine Aufzeichnung wird nach der Live-Veranstaltung auf der Website verf眉gbar sein.
- None.
- None.
HOLON,
To access the live conference call by telephone, please dial 1-866-744-5399 from the
Following the live webcast, a replay will be available on the Company's website.
础产辞耻迟听颁辞尘辫耻驳别苍
Compugen听is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive AI/ML powered computational discovery platform (Unigen鈩�) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902,听a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies.听GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage听immuno-oncology programs consists of research programs aiming to address new mechanisms to activate the immune system against cancer. Compugen听is headquartered in
Company contact:
Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
贰尘补颈濒:听[email protected]
Tel: +1听(628)听241-0071听
听
View original content:
SOURCE Compugen Ltd.
FAQ
When will Compugen (CGEN) release Q2 2025 earnings?
How can I access Compugen's Q2 2025 earnings call?
Will there be a replay available of Compugen's Q2 2025 earnings call?
What type of company is Compugen (CGEN)?
